In the N3RO Trial (N-3 fatty acids for
improvement in Respiratory Outcomes), we are investigating whether
giving very preterm infants (those born less than 29 weeks’ gestation) an extra
supply of an n-3 (or omega-3) fat called docosahexaenoic acid (DHA), improves important respiratory
outcomes associated with being born early.
The outcome of the trial has been published in the New England Journal of Medicine (NJEM): Docosahexaenoic
Acid and Bronchopulmonary Dysplasia in Preterm Infants. The paper reports the results of the N3RO
trial that involved 13 centres in Australia, New Zealand and Singapore and
showed that giving extra omega 3 fats to babies born <29 weeks has no effect
on chronic lung disease and may increase risk.